TrialBMC cancer2023

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).

Sylvie Lorenzen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.